Baxter International Inc. has recently released its 10-K report, providing a comprehensive overview of its operations and financials. The company, through its subsidiaries, offers a wide range of healthcare products globally. It operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care, serving various healthcare facilities and patients at home under physician supervision. The company's products include intravenous solutions, infusion systems, surgical equipment, patient monitoring technologies, respiratory health devices, and dialysis therapies and services.
In Item 12 of the report, Baxter International Inc. disclosed the security ownership of certain beneficial owners and management, as well as related stockholder matters. As of December 31, 2024, the company had 25,169,949 shares to be issued upon the exercise of outstanding options, warrants, and rights, with a weighted-average exercise price of $60.15. Additionally, there were 55,869,497 shares remaining available for future issuance under equity compensation plans, excluding the shares reflected in the outstanding options.
The report also highlighted that the company has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products. Furthermore, Baxter International Inc. has a collaborative research agreement with Miromatrix Medical Inc. aimed at advancing care for patients with acute liver failure. The company, which was incorporated in 1931 and is headquartered in Deerfield, Illinois, operates in approximately 100 countries and sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. The market has reacted to these announcements by moving the company's shares 1.1% to a price of $33.82. For more information, read the company's full 10-K submission here.
